Veracyte VCYT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Veracyte (VCYT) Business Model and Operations Summary
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Key Insights
Veracyte (VCYT) Core Market Data and Business Metrics
Latest Closing Price
$30.13Market Cap
$2.35 BillionPrice-Earnings Ratio
-231.77Total Outstanding Shares
77.95 Million SharesTotal Employees
824Dividend
No dividendIPO Date
October 30, 2013SIC Description
Services-medical LaboratoriesPrimary Exchange
NASDAQHeadquarters
6000 Shoreline Court, Suite 300, South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,095,343 Shares | 3.01 | 3/14/2025 | 3,302,156 Shares |
| 1,209,167 Shares | 2.8 | 2/28/2025 | 3,388,505 Shares |
| 758,519 Shares | 4.13 | 2/14/2025 | 3,131,797 Shares |
| 836,148 Shares | 3.77 | 1/31/2025 | 3,151,208 Shares |
| 764,066 Shares | 3.99 | 1/15/2025 | 3,047,480 Shares |
| 645,411 Shares | 4.33 | 12/31/2024 | 2,791,964 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-4.63 Million |
| Exchange Gains/Losses | $274,000 |
| Net Cash Flow From Investing Activities | $-4.63 Million |
| Net Cash Flow From Financing Activities, Continuing | $10.06 Million |
| Net Cash Flow, Continuing | $71.55 Million |
| Net Cash Flow From Operating Activities | $66.12 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-9.27 Million |
| Basic Average Shares | $76.26 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Benefits Costs and Expenses | $433.50 Million |
| Other Operating Expenses | $370.41 Million |
| Diluted Average Shares | $77.50 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $3.65 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $3.65 Million |
| Other Comprehensive Income/Loss | $3.65 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $12.91 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $1.28 Billion |
| Liabilities | $98.98 Million |
| Equity | $1.18 Billion |
| Wages | $30.74 Million |
| Current Assets | $356.85 Million |
| Noncurrent Liabilities | $28.67 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||